By  on May 28, 2014

PARIS — In a move to bolster its skin health activity, Nestlé said it is acquiring the rights to commercialize the aesthetic dermatology products Restylane, Perlane, Emervel, Dysport and Sculptra in the U.S. and Canada from Valeant Pharmaceuticals International for $1.4 billion in cash.

Nestlé said the U.S. and Canada together represent more than 50 percent of the global medical aesthetics market.

To Read the Full Article
SUBSCRIBE NOW

Tap into our Global Network

Of Industry Leaders and Designers

load comments
blog comments powered by Disqus